Eloxx Pharmaceuticals, Inc. (ELOX) financial statements (2020 and earlier)

Company profile

Business Address 950 WINTER STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
6/30/2017
6/30/2016
6/30/2015
6/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6549240136
Cash and cash equivalents2249240136
Short-term investments43      
Restricted cash and investments000    
Receivables0     0
Prepaid expense110   1
Other undisclosed current assets110000 
Total current assets:6750250147
Noncurrent Assets
Property, plant and equipment0000000
Intangible assets, net (including goodwill)     616
Goodwill     614
Intangible assets, net (excluding goodwill)      2
Deposits noncurrent assets   0000
Other noncurrent assets00     
Other undisclosed noncurrent assets1  681010
Total noncurrent assets:100681626
TOTAL ASSETS:685125692033
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7831012
Accounts payable2120001
Accrued liabilities5720001
Employee-related liabilities     00
Taxes payable00     
Debt3  0   
Derivative instruments and hedges, liabilities   2   
Due to related parties0      
Other liabilities    00 
Other undisclosed current liabilities0    (0)(0)
Total current liabilities:11833012
Noncurrent Liabilities
Long-term debt and lease obligation11      
Long-term debt, excluding current maturities11      
Liabilities, other than long-term debt   2470
Deferred tax liabilities, net  234 
Other liabilities    000
Derivative instruments and hedges, liabilities    13 
Other undisclosed noncurrent liabilities      4
Total noncurrent liabilities:11  2474
Total liabilities:22835576
Stockholders' equity
Stockholders' equity attributable to parent, including:454321151227
Common stock0000000
Treasury stock, value(2)(1)     
Additional paid in capital17213060122120119116
Accumulated other comprehensive income0      
Accumulated deficit(125)(86)(39)(122)(116)  
Other undisclosed stockholders' equity attributable to parent   00(107)(88)
Total stockholders' equity:454321151227
Other undisclosed liabilities and equity0      
TOTAL LIABILITIES AND EQUITY:685125692033

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
6/30/2017
6/30/2016
6/30/2015
6/30/2014
Revenues    000
Revenue, net  000
Cost of revenue   (3)(7) (0)
Gross profit:   (3)(7)0(0)
Operating expenses(53)(48)(20)(2)(4)(24)(9)
Other undisclosed operating income (loss)     6(0)
Operating loss:(53)(48)(20)(5)(11)(18)(9)
Nonoperating income (expense)01(0)020 
Investment income, nonoperating   020 
Foreign currency transaction loss, before tax  (0)    
Other nonoperating income01     
Interest and debt expense(1)(0)(1)   (0)
Other undisclosed income from continuing operations before equity method investments, income taxes 00    
Loss from continuing operations before equity method investments, income taxes:(54)(47)(21)(4)(9)(18)(9)
Other undisclosed income (loss) from continuing operations before income taxes   (2)0  
Loss from continuing operations before income taxes:(54)(47)(21)(7)(9)(18)(9)
Income tax expense (benefit) (0) 11  
Other undisclosed loss from continuing operations(0)      
Net loss:(54)(47)(21)(6)(8)(18)(9)
Other undisclosed net income (loss) attributable to parent1 (0)  00
Net loss attributable to parent:(53)(47)(21)(6)(8)(18)(9)
Preferred stock dividends and other adjustments   (0)(0)(1)(5)
Net loss available to common stockholders, diluted:(53)(47)(21)(6)(8)(19)(14)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
6/30/2017
6/30/2016
6/30/2015
6/30/2014
Net loss:(54)(47)(21)(6)(8)(18)(9)
Comprehensive loss:(54)(47)(21)(6)(8)(18)(9)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1   (0)(1)(5)
Comprehensive loss, net of tax, attributable to parent:(53)(47)(21)(6)(8)(19)(14)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: